Crestor Campaign Makes FDA Complain; "Clearly The Best" Given A Rest
This article was originally published in The Pink Sheet Daily
Executive Summary
An FDA "untitled" letter takes issue with AstraZeneca's presentation of comparative claims to other statins in an ad campaign that states Crestor is "clearly the best." This is the second ad division letter sent to AstraZeneca for Crestor promotions. AstraZeneca says the FDA-cited campaign concluded at the end of 2004.
You may also be interested in...
Crestor's New Ad: Dr. Seuss Is Out, "Direct" Presentation Of Benefit/Risk Is In
AstraZeneca launches TV commericals that touts Crestor's 52% LDL reduction efficacy. The ad notes the Adult Treatment Panel III July 2004 recommendation for more aggressive therapy. The risk information is presented by an on-screen spokesman instead of a voiceover.
Crestor's New Ad: Dr. Seuss Is Out, "Direct" Presentation Of Benefit/Risk Is In
AstraZeneca launches TV commericals that touts Crestor's 52% LDL reduction efficacy. The ad notes the Adult Treatment Panel III July 2004 recommendation for more aggressive therapy. The risk information is presented by an on-screen spokesman instead of a voiceover.
Aggrenox Journal Ad Improperly Suggests Superiority To Plavix, FDA Says
The paper referenced in the ad is "a historically controlled trial that is inadequate to support a superiority claim," the FDA ad division letter states. The agency also cites the Aggrenox ad for omitting risk information.